Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tengion bioengineered bladder trial

This article was originally published in The Gray Sheet

Executive Summary

Firm initiates enrollment Jan. 5 in a 10-patient, Phase II clinical trial of its bioengineered bladder-shaped collagen scaffold to treat bladder malfunctions that can lead to kidney failure and incontinence. Physicians take healthy cells from the patient's bladder and send them to Tengion, where they are grown and attached to the biodegradable collagen scaffold. The product is then surgically implanted into the patient's own failing bladder (1"The Gray Sheet" April 10, 2006, p. 15)...
Advertisement
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT024369

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel